Nutriband Inc. (NTRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRB Stock Summary
- The ratio of debt to operating expenses for NUTRIBAND INC is higher than it is for about only 7.68% of US stocks.
- NTRB's price/sales ratio is 13.18; that's higher than the P/S ratio of 92.3% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for NUTRIBAND INC; that's greater than it is for just 8.09% of US stocks.
- If you're looking for stocks that are quantitatively similar to NUTRIBAND INC, a group of peers worth examining would be VISL, MRAI, DH, SATL, and XMTR.
- NTRB's SEC filings can be seen here. And to visit NUTRIBAND INC's official web site, go to nutriband.com.
NTRB Valuation Summary
- NTRB's price/earnings ratio is -4.1; this is 118.14% lower than that of the median Healthcare stock.
- NTRB's price/sales ratio has moved NA NA over the prior 64 months.
Below are key valuation metrics over time for NTRB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NTRB | 2023-03-17 | 13.2 | 2.8 | -4.1 | -3.7 |
| NTRB | 2023-03-16 | 12.3 | 2.6 | -3.8 | -3.4 |
| NTRB | 2023-03-15 | 12.8 | 2.7 | -4.0 | -3.6 |
| NTRB | 2023-03-14 | 12.3 | 2.6 | -3.8 | -3.4 |
| NTRB | 2023-03-13 | 13.0 | 2.7 | -4.0 | -3.7 |
| NTRB | 2023-03-10 | 13.6 | 2.9 | -4.2 | -3.9 |
NTRB Price Target
For more insight on analysts targets of NTRB, see our NTRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
NTRB Stock Price Chart Interactive Chart >
NTRB Price/Volume Stats
| Current price | $3.46 | 52-week high | $8.14 |
| Prev. close | $3.25 | 52-week low | $2.81 |
| Day low | $3.46 | Volume | 11,604 |
| Day high | $3.52 | Avg. volume | 10,338 |
| 50-day MA | $3.75 | Dividend yield | N/A |
| 200-day MA | $4.07 | Market Cap | 27.10M |
Nutriband Inc. (NTRB) Company Bio
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida
Latest NTRB News From Around the Web
Below are the latest news stories about NUTRIBAND INC that investors may wish to consider to help them evaluate NTRB as an investment opportunity.
Nutriband Inc Joins Webull Corporate Communications Service PlatformNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. |
Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert CommitteeNutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has been selected for the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery Systems. |
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health RegisterNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador's Health Register (Registro Sanitar Ecuador) to permit the distribution of certain medical devices and cosmetic products in South America. |
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle ConferenceNutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom. |
Nutriband Inc. Commences Trading on Upstream Under NTRBNutriband among the first issuers to dual list on Upstream ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange |
NTRB Price Returns
| 1-mo | -13.07% |
| 3-mo | -8.46% |
| 6-mo | -13.28% |
| 1-year | -16.02% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.02% |
| 2022 | -64.24% |
| 2021 | -32.80% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...